Optinose Inc Revenue Growth Rates (OPTN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Optinose Inc   (NASDAQ: OPTN)
 

OPTN's Revenue Growth by Quarter and Year

Optinose Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

OPTN Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 27.27
FY 27.27

OPTNs Annual Revenue
Optinose Inc 's Revenue in the fiscal year 2024 $ 78.23 millions
Optinose Inc 's Revenue in the fiscal year 2023 $ 70.99 millions
Optinose Inc 's Revenue in the fiscal year 2022 $ 76.28 millions
Optinose Inc 's Revenue in the fiscal year 2021 $ 74.65 millions
Optinose Inc 's Revenue in the fiscal year 2020 $ 49.12 millions




OPTN Revenue first quarter 2025 Y/Y Growth Comment
Optinose Inc showed record Revenue increase in the first quarter 2025 with 83.27% from the first quarter 2025 2024, to $ 27.27 millions.

Looking into first quarter 2025 results within Major Pharmaceutical Preparations industry 30 other companies have achieved higher Revenue growth. While Optinose Inc ' s Revenue jump of 83.27% ranks overall at the positon no. 174 in the first quarter 2025.


OPTN Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December - 12.89 % -4.79 % -7.33 %
3rd Quarter September - 3.13 % -1.29 % -8.02 %
2nd Quarter June - 5.35 % -5.49 % 12.09 %
1st Quarter March 83.27 % 25.57 % -19.72 % 23.41 %
FY   - 10.21 % -6.95 % -

Financial Statements
Optinose Inc 's first quarter 2025 Revenue $ 27.27 millions OPTN's Income Statement
Optinose Inc 's first quarter 2024 Revenue $ 14.88 millions Quarterly OPTN's Income Statement


OPTN Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - 9.69 % 0.2 % 3.88 %
3rd Quarter September - -0.24 % 1.9 % -2.43 %
2nd Quarter June - 37.7 % 64.14 % 39.43 %
1st Quarter March 21.63 % -25.08 % -43.19 % -34.43 %
FY (Year on Year)   - 10.21 % -6.95 % -


Back to OPTN Growth rate Comparisons >> Back to OPTN Growth rate Comparisons >>


Revenue first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #31
Healthcare Sector #63
Overall #174

Revenue Y/Y Growth Statistics
High Average Low
83.27 % 25.23 % -19.74 %
(Sep 30 2021)   (Jun 30 2023)
Revenue first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #31
Healthcare Sector #63
Overall #174
Revenue Y/Y Growth Statistics
High Average Low
83.27 % 25.23 % -19.74 %
(Sep 30 2021)   (Jun 30 2023)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Optinose Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
85.67 % 12.98 % -43.2 %
(Sep 30 2019)  


OPTN's I. Quarter Q/Q Revenue Comment
Optinose Inc achieved in the I. Quarter 2025 above company average sequential Revenue jump of 21.63%, to $ 27.27 millions, from $22.42 millions in the fourth quarter.
OPTN is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 38 other companies have achieved higher Revenue quarter on quarter growth. While Optinose Inc 's Revenue growth quarter on quarter, overall rank is 333.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #39
Healthcare Sector #77
Overall #333
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #39
Healthcare Sector #77
Overall #333
Revenue Q/Q Growth Statistics
High Average Low
85.67 % 12.98 % -43.2 %
(Sep 30 2019)  


OPTN's I. Quarter Q/Q Revenue Comment
Optinose Inc achieved in the I. Quarter 2025 above company average sequential Revenue jump of 21.63%, to $ 27.27 millions, from $22.42 millions in the fourth quarter.
OPTN is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 38 other companies have achieved higher Revenue quarter on quarter growth. While Optinose Inc 's Revenue growth quarter on quarter, overall rank is 333.


Optinose Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)
Cumulative Revenue 12 Months Ending $ 90.62 $ 78.23 $ 75.67 $ 75.06 $ 74.02
Y / Y Revenue Growth (TTM) 22.42 % 10.2 % 5.13 % 3.91 % 0.9 %
Year on Year Revenue Growth Overall Ranking # 1767 # 2710 # 2575 # 1704 # 1591
Seqeuential Revenue Change (TTM) 15.84 % 3.38 % 0.82 % 1.4 % 4.27 %
Seq. Revenue Growth (TTM) Overall Ranking # 1658 # 2269 # 1985 # 1322 # 1521


Cumulative Revenue growth Comment
Optinose Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 22.42% year on year, to $ 91 millions if the fiscal year would have ended in Mar 31 2025.
Optinose Inc 's trailing twelve months Revenue growth was higher than company's average 19.35% and higher than 10.2% growth in Dec 31 2024.
But from twelve months ended Dec 31 2024 rise was beneth at 15.84 % from $78.23 millions achieved in the period from Dec 31 2024 to Mar 31 2024.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at19.35%.
The momentum is even more impressive from twelve months ended Dec 31 2024 exhibited at 15.84 % increase from $78.23 millions in the period from Dec 31 2024 to Mar 31 2024.

In the Healthcare sector 271 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1767, from total ranking in previous quarter at 2710.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 106
Healthcare Sector # 272
Overall # 1767

Revenue TTM Y/Y Growth Statistics
High Average Low
56.19 %
 19.35 %
-9.34 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 106
Sector # 294
S&P 500 # 1658
Cumulative Revenue growth Comment
Optinose Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 22.42% year on year, to $ 91 millions if the fiscal year would have ended in Mar 31 2025.
Optinose Inc 's trailing twelve months Revenue growth was higher than company's average 19.35% and higher than 10.2% growth in Dec 31 2024.
But from twelve months ended Dec 31 2024 rise was beneth at 15.84 % from $78.23 millions achieved in the period from Dec 31 2024 to Mar 31 2024.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at19.35%.
The momentum is even more impressive from twelve months ended Dec 31 2024 exhibited at 15.84 % increase from $78.23 millions in the period from Dec 31 2024 to Mar 31 2024.

In the Healthcare sector 271 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1767, from total ranking in previous quarter at 2710.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 106
Healthcare Sector # 272
Overall # 1767

Revenue TTM Y/Y Growth Statistics
High Average Low
56.19 %
19.35 %
-9.34 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 106
Sector # 294
S&P 500 # 1658




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
OPTN's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Mar 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2025
Beyond Air Inc 145.11%$ 145.106 millions
Eton Pharmaceuticals Inc 140.63%$ 140.631 millions
C4 Therapeutics Inc 138.17%$ 138.170 millions
Springworks Therapeutics Inc 133.68%$ 133.681 millions
Lyell Immunopharma Inc 133.33%$ 133.333 millions
Generation Bio Co 114.91%$ 114.905 millions
Kymera Therapeutics Inc 114.83%$ 114.834 millions
Newamsterdam Pharma Company N v 112.56%$ 112.562 millions
Hims and Hers Health Inc 110.61%$ 110.608 millions
Eyepoint Inc 109.29%$ 109.286 millions
Bluebird Bio Inc 108.43%$ 108.432 millions
Legend Biotech Corporation107.52%$ 107.523 millions
Nuo Therapeutics Inc 106.49%$ 106.491 millions
Vyne Therapeutics Inc 106.12%$ 106.122 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________105.44%$ 105.439 millions
Xencor Inc104.61%$ 104.613 millions
Coya Therapeutics Inc 103.32%$ 103.318 millions
Alaunos Therapeutics Inc 100.00%$ 100.000 millions
Travere Therapeutics Inc 97.54%$ 97.544 millions
Krystal Biotech Inc 94.88%$ 94.880 millions
Avadel Pharmaceuticals Plc94.83%$ 94.830 millions
Scpharmaceuticals Inc 92.59%$ 92.593 millions
Tg Therapeutics Inc 90.40%$ 90.402 millions
Cytokinetics Incorporated89.10%$ 89.102 millions
Aclarion Inc 87.77%$ 87.769 millions
Regen Biopharma Inc 86.68%$ 86.678 millions
Neuronetics Inc 85.73%$ 85.733 millions
2seventy Bio Inc 84.46%$ 84.463 millions
Optinose Inc 83.27%$ 83.266 millions
Profound Medical Corp 82.14%$ 82.140 millions


About Optinose Inc Revenue Growth Rates (OPTN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Optinose Inc (CIK 1494650).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001494650-25-000072
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Optinose Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.